RE:Don Dementia Kindvalue, your post has zero value. You are clearly just showing up here and putting on the Bashy McBashface show. I doubt if you have any clue as to the mechanism of action of apabetalone, its clinical development, proven safety, or any details of the BETonMACE cognition sub-study. Without seeing the data, we can't say for sure whether the cognition sub-study was a success. However, in light of how the market has valued Biogen/Eisai's BAN2401 and aducanumab roller coaster, it is not very far fetched for this little known undervalued company called Resverlogix to get quite the attention and valuation if the data revealed Thursday and Friday looks good. Will there need to be a follow up registration trial(s)? Of course! But it might not be Resverlogix doing that trial if you know what I mean. Tick tock for CTAD! BDAZ